Table 3 Validations of predicted drug indications for RA and IBD from consensus drug lists, ordered by drug list ranking
Rheumatoid Arthritis (RA) | Reference for Validation | Inflammatory Bowel Disease (IBD) | Reference for Validation |
|---|---|---|---|
Alvocidib | Sekine et al. J Immunol. 180(3):1954–1961 (2008) [51] | Sulfasalazine | Klotz et al. N Engl J Med. 303(26):1499–1502 (1980) [105] |
Karenitecin | Liu et al. Med Res Rev. 35(4):753-89 (2015) [53] | Olsalazine | Baumgart et al. Lancet. 369(9573):1641–1657 (2007) [106] |
Sulindac | Brogden et al. Drugs. 16(2):97–114 (1978) [97] | Tetomilast | Keshavarzian et al. Expert Opin Investig Drugs. 16(9):1489–1506 (2007) [107] |
Sunitinib | Fuyura et al. Mod Rheumatol. 24(3):487–491 (2013) [52] | Inosine | Mabley et al. Am J Physiol Gastrointest Liver Physiol. 284(1):G138-G144 (2003) [108] |
INCB28050 | Taylor et al. Ann Rheum Dis. 73:A31 (2014) [99] | Thioproperazine | Lechin et al. J Clin Gastroenterol. 4(5):445–450 (1982) [56] |
Amodiaquine | Kersley et al. Lancet. 2(7108):886–888 (1959) [54] | Etoricoxib | El Miedany et al. Am J Gastroenterol. 101(2):311–317 (2006) [109] |
Raltitrexed | van der Heijden et al. Scand J Rheumatol. 43(1):9–16 (2014) [100] | Balsalazide | Carter et al. Gut. 53(Suppl 5):V1-V16 (2004) [110] |
BIRB 796 | Page et al. Arthritis Rheum. 62(11):3221–3231 (2010) [101] | Thalidomide | Gerich et al. Ailment Pharmacol Ther. 41(5):429–437 (2015) [59] |
Adalimumab | Weinblatt et al. Arthritis Rheum. 48(1):35–45 (2003) [102] | Rosiglitazone | Ramakers et al. J Clin Immunol. 27(3):275–283 (2007) [57] |
Etanercept | Moreland et al. Ann Intern Med. 130(6):478–486 (1999) [103] | Irbesartan | Ray et al. Gut. 62(S1):A525-A525 (2013) [60] |
Minocycline | O’Dell et al. Arthritis Rheum. 40(5):842–848 (1997) [104] | Chloroquine | Nagar et al. Int Immunopharmacol. 21(2):328–335 (2014) [111] |